Best AAV / Gene Therapy CDMOs in Asia

← All AAV CDMOs Best Clean FDA History Commercial Scale

Region: USA Europe Asia

CDMOs tracked

Fully scored

With FDA records

FDA inspections

EMA/MHRA GMP certs

For Asia-manufactured aav / gene therapy programs, Pharmaron Biologics, Ajinomoto Bio-Pharma Services, and Lotte Biologics lead CDMO Signal's ranking of aav / gene therapy CDMOs with confirmed Asian manufacturing sites. Filtered from the global directory of 56 scored aav / gene therapy CDMOs to 10 with Asia-Pacific facility presence. Asian CDMOs cover a range of regulatory jurisdictions — PMDA (Japan), NMPA (China), MFDS (South Korea), CDSCO (India) — each with distinct requirements. For sponsors supplying US and EU markets, cross-jurisdictional regulatory posture (FDA and EMA/MHRA inspection history on Asian facilities) is typically the qualifying signal. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

Adeno-associated virus (AAV) is the dominant delivery platform for in vivo gene therapy, from rare-disease programs to larger systemic indications. Rising demand has pushed CDMOs to scale suspension processes and tighten full/empty capsid analytics.

Selecting an AAV CDMO hinges on serotype experience, suspension vs adherent platform, full/empty capsid separation, and a proven regulatory record. The rankings below score each manufacturer on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 6 NAI (no action), 3 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Denmark (18), United States (9), Germany (4), Ireland (2), Italy (2).

Last updated 2026-08-01. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	PB Pharmaron Biologics San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China	86.9	100.0	3 insp · 0 GMP	Available	0 programs
2	AJ Ajinomoto Bio-Pharma Services San Diego, CA · Osaka, JP	85.6	100.0	0 insp · 1 GMP	—	0 programs
3	LB Lotte Biologics Incheon, KR · Syracuse, NY	83.7	100.0	1 insp · 0 GMP	—	0 programs
4	WB2 WuXi Biologics Shanghai, CN · Wuxi, CN	83.7	100.0	0 insp · 4 GMP	—	0 programs
5	AG AGC Biologics Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP	80.6	99.9	2 insp · 23 GMP	Available	2 programs
6	GZ Genezen Indianapolis, IN · Lexington, MA	70.7	84.1	3 insp · 0 GMP	Available	0 programs
7	IU Indiana University Vector Production Facility Indianapolis, IN	66.2	—	—	—	47 programs
8	UB uBriGene Biosciences Shanghai, CN · Boston, MA	60.5	—	—	—	0 programs
9	CoJourney Inc. Horsham, PA (US HQ); Hangzhou, China (primary GMP manufacturing)	60.0	—	—	Limited	0 programs
10	HX Helixmith Seoul, KR	59.0	—	—	—	0 programs
—	Canton Biologics Guangzhou, China	Profiled	—	—	—	0 programs

How we score CDMOs →

What to evaluate in a AAV / Gene Therapy CDMO

Platform & scale

Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.

Capsid quality

Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.

Regulatory readiness

For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.

Capacity & timelines

AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.

Regulatory landscape across PMDA (Japan), NMPA (China), MFDS (South Korea)

Asian biopharma manufacturing spans multiple national regulators. PMDA (Japan) is generally regarded as one of the most stringent in Asia, with GMP requirements broadly aligned with FDA and EMA. NMPA (China) has substantially strengthened its GMP framework over the past decade, and Chinese CDMOs increasingly hold FDA and EMA certifications alongside NMPA registration. MFDS (South Korea) certification is standard for Korean CDMOs. For sponsors supplying US or EU markets, the qualifying signal for an Asian CDMO is typically FDA and EMA inspection history on the specific facility — which the Signal Score's Quality Compliance pillar captures directly.

Which Asian CDMOs cover FDA (US) and EMA/MHRA (Europe) regulatory geographies?

Asian CDMOs with US FDA and European EMA/MHRA inspection history are qualified to supply global markets; those without cross-jurisdictional inspection posture are typically limited to their home-market regulatory scope. The Signal Score's Quality Compliance pillar includes FDA + EMA + MHRA data directly, so Asian CDMOs with cross-jurisdictional certification typically rank higher on this pillar than home-market-only competitors. Sponsors evaluating an Asian CDMO for a US or EU program should cross-check with the US region ranking and Europe region ranking — CDMOs appearing across regions have demonstrated multi-jurisdictional posture.

Recent US regulatory events affecting Asian CDMO selection (WuXi 1260H, BioSecure Act considerations)

Asian CDMOs — particularly Chinese-headquartered players — are subject to US regulatory events that affect sponsor risk assessment. The US Department of Defense's 1260H list (which added WuXi AppTec in June 2026) and the BioSecure Act (proposed federal legislation restricting federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies) are both active considerations. CDMO Signal's platform does not encode US political risk into the Signal Score directly — the composite reflects regulatory quality, operations, financial stability, and capacity signals. Sponsors weighing an Asian CDMO for a US-supplying program should evaluate US regulatory risk separately as a distinct decision layer alongside the Signal Score-based capability assessment.

AAV / Gene Therapy CDMOs — Frequently Asked Questions

Who are the top AAV / Gene Therapy CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked AAV / Gene Therapy CDMOs include Pharmaron Biologics, Ajinomoto Bio-Pharma Services, Lotte Biologics. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many AAV / Gene Therapy CDMOs have FDA inspection records?

CDMO Signal tracks 4 AAV / Gene Therapy CDMOs with FDA inspection records and 28 EMA/MHRA GMP certificates across the group.

What should I look for in an AAV CDMO?

Look for serotype experience, a scalable suspension platform, strong full/empty capsid analytics, and a clean FDA and EMA/MHRA record. Match validated bioreactor scale to your dose and indication.

What's the difference between AAV and lentiviral CDMOs?

AAV is non-integrating and produced at higher volumes for in vivo gene therapy. Lentivirus integrates into the genome, is made under BSL-2 with RCL testing, and is used mainly for ex vivo cell engineering like CAR-T.

Related modalities

Lentiviral Vector CDMOs Gene Editing CDMOs Plasmid DNA CDMOs

Other Modalities

CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC